Recurrence and survival following microwave, radiofrequency ablation, and hepatic resection of colorectal liver metastases: A systematic review and network meta-analysis.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Affiliation
University Hospitals Birmingham NHS Foundation Trust; Assistance Publique des Hopitaux de Paris; San Raffaele HospitalPublication date
2021-06-04
Metadata
Show full item recordAbstract
Background: Gold standard for colorectal liver metastases (CRLM) remains hepatic resection (HR). However, patients with severe comorbidities, unresectable or deep-situated resectable CRLM are candidates for ablation. The aim of the study was to compare recurrence rate and survival benefit of the microwave ablation (MWA), radiofrequency ablation (RFA) and HR by conducting the first network meta-analysis. Data sources: Systematic search of the literature was conducted in the electronic databases. Both updated traditional and network meta-analyses were conducted and the results were compared between them. Results: HR cohort demonstrated significantly less local recurrence rate and better 3- and 5-year disease-free (DFS) and overall survival (OS) compared to MWA and RFA cohorts. HR cohort included significantly younger patients and with significantly lower preoperative carcinoembryonic antigen (CEA) by 10.28 ng/mL compared to RFA cohort. Subgroup analysis of local recurrence and OS of solitary and ≤ 3 cm CRLMs did not demonstrate any discrepancies when compared with the whole sample. Conclusions: For resectable CRLM the treatment of choice still remains HR. MWA and RFA can be used as a single or adjunct treatment in patients with unresectable CRLM and/or prohibitive comorbidities.Citation
Gavriilidis P, Roberts KJ, de'Angelis N, Aldrighetti L, Sutcliffe RP. Recurrence and survival following microwave, radiofrequency ablation, and hepatic resection of colorectal liver metastases: A systematic review and network meta-analysis. Hepatobiliary Pancreat Dis Int. 2021 Aug;20(4):307-314. doi: 10.1016/j.hbpd.2021.05.004. Epub 2021 Jun 4.Type
ArticleAdditional Links
https://www.sciencedirect.com/journal/hepatobiliary-and-pancreatic-diseases-internationalPMID
34127382Publisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.hbpd.2021.05.004